Changing responsiveness of luteal cells of the marmoset monkey (Callithrix jacchus) to luteotrophic and luteolytic agents during normal and conception cycles.
Dispersed marmoset luteal cells were incubated for 2 h and progesterone production measured after exposure to hCG, cloprostenol, dibutyryl cAMP, PGF-2 alpha, PGF-2, adrenaline or melatonin. The cells were studied on Days 6, 14 and 20 after ovulation in conception and non-conception cycles. Luteal cells from Day 14 non-pregnant marmosets were compared with human luteal cells taken in the mid-luteal phase. All the treatments stimulated progesterone production including cloprostenol, which is luteolytic when administered to the marmoset in vivo, but the degree of response varied with the stage of the cycle or pregnancy and between marmoset and human luteal cells. In the marmoset, overall analysis of the effect of the treatments showed that, on Day 6 after ovulation, there was no significant effect of any of the treatments in cells from pregnant or non-pregnant animals. In contrast, luteal cells from non-pregnant animals on Day 14 showed a significant response to the treatments (F (8,41) = 2.79, P less than 0.0145) whereas cells from pregnant Day-14 animals were responsive; in cells from pregnant animals, the control production of progesterone was high and already equivalent to the levels stimulated by the treatments. By Day 20, cells from pregnant animals produced lower control concentrations of progesterone than did those on Day 14 and there was a significant overall effect of the treatments (F (8,33) = 3.78, P less than 0.003). These results show that the marmoset CL gains responsiveness to treatment between Days 6 and 14 after ovulation in the non-pregnant cycle. In pregnancy, on Day 14, 2 days after attachment of the embryo, the high control concentrations of progesterone and absence of response to treatment suggest that an embryo message may have affected the CL, providing an endogenous stimulus.
Webley
G E
GE
MRC/AFRC Comparative Physiology Group, Institute of Zoology, London, UK.
Richardson
M C
MC
Summers
P M
PM
Given
A
A
Hearn
J P
JP
D000818:Animals; D003994:Bucladesine / Q000494:pharmacology; D002144:Callithrix; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D003008:Cloprostenol / Q000494:pharmacology; D003338:Corpus Luteum / Q000187:drug effects / Q000502:physiology*; D003340:Corpus Luteum Maintenance / Q000187:drug effects*; D015237:Dinoprost / Q000494:pharmacology; D004837:Epinephrine / Q000494:pharmacology; D004971:Estrus / Q000502:physiology*; D005260:Female; D006801:Humans; D008550:Melatonin / Q000494:pharmacology; D011247:Pregnancy; D011374:Progesterone / Q000096:biosynthesis*
D006063:Chorionic Gonadotropin; D003008:Cloprostenol; D011374:Progesterone; D003994:Bucladesine; D015237:Dinoprost; D008550:Melatonin; D004837:Epinephrine